An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD)

Grant

Date/time Interval

  • May 1, 2016 - June 30, 2023

    • Awarded By

    Total Award Amount

  • 27344.00

    • Direct Costs

  • 18601.00

    • Sponsor Award Id

    • Contributor

  • Marissa Dean   Investigator  
  • Victor Sung   Principal Investigator